CKD-MBD CKD mineral bone disorder

Size: px
Start display at page:

Download "CKD-MBD CKD mineral bone disorder"

Transcription

1 CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature death Disorders of bone and mineral metabolism Revised classification CKD CKD mineral bone disorder Systemic disorder of mineral and bone metabolism including one or more of: Abnormalities of Ca 2+, PO 4, PTH, or Vit D Abnormalities of bone turnover, mineralization, volume, strength Vascular or other soft tissue calcification KDIGO 2013 KDIGO Kidney International 2009; 76 (Suppl 113): S1 S130 Renal osteodystrophy Skeletal pathology component of the syndrome Histomorphometry Normal serum levels of Ca 2+ and PO 4 maintained by 3 hormones PTH 1,25(OH) 2 D calcitriol Phosphatonins FGF23 KDIGO 2009 Act on kidney, bone and intestine 1

2 Kidneys responsible for: PTH mediated PO 4 excretion and Ca 2+ reabsorption Increased PO 4 excretion mediated by FGF23 Conversion of 25(OH)D to 1,25(OH) 2 D Disturbances in mineral metabolism are common occurring early in CKD Begins in CKD 3: Unable to fully excrete PO 4 causing in FGF23 Compensatory 2 o hyperparathyroidism production of 1,25(OH) 2 D Changes in FGF23 and PTH occur first Isakova T 2011 Kidney Int 79 As CKD progresses PO 4 will tend to Ca 2+ will at first tend to In more advanced disease especially for patients on dialysis, hypercalcaemia may occur Hyperplasia of PTh glands Iatrogenic Calcitriol, calcium containing PO 4 binders Renal osteodystrophy (ROD) Seen universally in those on dialysis Majority of patients with CKD 3b 5 High bone turnover - predominant hyperpth Low bone turnover adynamic (aluminium induced) osteomalacia Mixed - hyperpth and mineralisation defect Histology may transform from one category to another Osteoporosis may coexist with ROD hyperpth Vitamin D deficiency Acidosis sclerostin Fracture rates are about 4 fold higher and to a certain extent independent of BMD Osteosclerosis may include woven bone Cortical bone loss may outstrip trabecular Jamal S Osteopor Int 2012; 23 2

3 Clinical manifestations Fracture risk higher Vascular calcification Systolic hypertension, cardiovascular disease Heterotopic mineralisation Skin: calciphylaxis skin necrosis Lung: restrictive lung disease Heart arrhythmias, CCF Tumoral calcinosis: periarticular Bone pain Esp low bone turnover Medical management of Treatments have evolved from better understanding of pathophysiology Conspicuous lack of robust evidence esp in context of clinically relevant outcomes Cunningham J The spectrum of bone and mineral disorders in CKD. OUP, 2010 Diagnosis of To define and monitor : Measure PTH, 25(OH)D, calcium and phosphate Serum FGF23 not routinely measured Bone markers, radiographs, bone biopsies not commonly used BUT Bone specific alkaline phosphatase (balp) probably is useful Diagnosis of No test other than bone biopsy identifies subtypes of bone disease in CKD BUT Not clear that bone biopsy result: is clinically important or can be used to direct treatment Alshayeb and Quarles. Primer on the Metabolic Bone Diseases and disorders of Mineral Metabolism Ch 78 p Clinical practice guidelines by National Kidney Foundation: Kidney disease: Outcomes Quality Initiative KDOQI 2003 Kidney Disease: Improving Global outcomes KDIGO 2009 KDIGO More emphasis on lack of evidence! Treatment Goals Aim for calcium and PO 4 in normal range PTH optimum level unknown except CKD 5D where aim for 2 to 9 x ULN Aim for normal PTH in CKD 3 As CKD advances aim for PTH no lower than 2.5 to 3 times the ULN Avoid adynamic bone disease Esp ESRD, elderly, diabetes 3

4 Treatment Goals Rationale for PTH PTH too high leads to progressive PTh bone disease, fractures, tertiary hyperparathyroidism, parathyroidectomy Association with cardiovascular events and death PTH too low Increases risk of low bone turnover Phosphate binders Ca 2+ salts (acetate binds more PO 4 than carbonate) Risk of hypercalcaemia Sevalamer Avoids hypercalcaemia GI side effects Binds tacrolimus, frusemide Lanthanum Avoids hypercalcaemia Better tolerated Controlling PTH levels Calcitriol or alfacalcidol and/or calcimimetics Titrate against PTH levels Look for trends in PTH levels Take into account calcium and PO 4 levels Calcimimetics lower Ca 2+ and PO 4 Vitamin D analogues increase Ca 2+ and PO 4 Controlling PTH levels Vitamin D3/D2 supplements Worth correcting vitamin D deficiency/insufficiency in all Peripheral hydroxylation in cardiovascular and immune system Association with better clinical outcomes Vitamin D supplements can modestly suppress PTH in CKD 3-4 KDIGO 2009 Controlling PTH levels Parathyroidectomy Most severe forms of hyperparathyroidism Medical management has failed Usually ESRD Indications Severe hypercalcaemia or hyperphosphataemia Symptomatic bone disease Calciphylaxis KDIGO 2009 Osteoporosis 24% CrCl <35 50% CrCl < 35 if >80 y/o Klawansky OI

5 Percent Incidence at Month 36 Fractures in CKD could be due to osteoporosis, or both CKD 1-3 RCTs include patients with CKD 1 to 3 so OK to diagnose and treat as usual Preferably correct any biochemical abnormalities of CKD 4-5 DXA less reliable We do measure BMD in patients with fractures Vertebral imaging can be useful Not sure if antiresorptives effective Antiresorptives may well be harmful if Adynamic bone disease or osteomalacia Low PTH and/or low balp My own opinion Data for antiresorptives CKD 4 Post hoc analyses Risedronate Denosumab Limited vertebral fracture data Safety looked alright Consistent risk reduction in vertebral fracture at 36 months by baseline CrCl in FREEDOM N Placebo (N=3906) DMAb (N=3902) All N = number of randomized subjects. N1 = number of randomized subjects with an evaluation during the time period of interest. There were no subjects with a CrCl < 15. P < 0.05 The interaction terms were NOT statistically significant, indicating no difference in effect of DMAb by level of renal function SA Jamal Oral Abstract ASBMR Denosumab Be very careful if GFR < 30 Risk of hypocalcaemia Can be profound and prolonged if CKD 5 Do not use it if adynamic bone disease Suggest : do not use in CKD 5 MHRA safety update 2012 and my own opinion Practical message In patient with severe renal disease having low trauma fractures with low BMD and no clear evidence of low bone turnover Reasonable to consider oral risedronate once per fortnight IV ibandronate once per 3 to 6 months Otherwise treat and preferably have patient on calcitriol/alfacalcidol 5

6 Renal transplantation Practical message Most things get better! Bone strength Sometimes best to wait for transplant rather than try and tackle their bone disease with unproven treatments Further reading KDIGO guidelines for Kidney International 2009; 76 (Suppl 113): S1 S130 Primer on the Metabolic Bone Diseases and disorders of Mineral Metabolism, 8 th Edition, Rosen CJ (Ed) Wiley-Blackwell, Chapters 77 and 78 Harding KA et al ASBMR Annual Meeting 2000 Further reading The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease, Second edition, Olgaard K, Salusky S, Silver J (Eds) OUP,

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker

More information

Metabolic Bone Disease Related to Chronic Kidney Disease

Metabolic Bone Disease Related to Chronic Kidney Disease Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009. http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording

More information

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man

More information

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker

More information

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD

More information

Contents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian

Contents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist

More information

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School

More information

Management of mineral and bone disorders in renal transplant recipients

Management of mineral and bone disorders in renal transplant recipients Nephrology 22, Suppl. 2 (2017) 65 69 Management of mineral and bone disorders in renal transplant recipients MATTHEW J DAMASIEWICZ 1,3 and PETER R EBELING 2,3,4 Departments of 1 Nephrology, and 2 Endocrinology,

More information

Cinacalcet treatment in advanced CKD - is it justified?

Cinacalcet treatment in advanced CKD - is it justified? Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to

More information

Bone Disorders in CKD

Bone Disorders in CKD Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis

More information

chapter 1 & 2009 KDIGO

chapter 1 & 2009 KDIGO http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3

More information

Bone Disease after Kidney Transplantation

Bone Disease after Kidney Transplantation Bone Disease after Kidney Transplantation BTS March 2018 Dr Arif Khwaja PhD, FRCP Sheffield Kidney Institute Clinical case 47 year old female FSGS DBD 2007 egfr 25mls/min. Sirolimus, Azathioprine and prednisolone

More information

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019 Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal

More information

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE

More information

PRIMARY HYPERPARATHYROIDISM

PRIMARY HYPERPARATHYROIDISM PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and

More information

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia NSW Therapeutic Advisory Group Level 5, 376 Victoria Street PO Box 766 Darlinghurst NSW 2010 Phone: 61 2 8382 2852 Fax: 61 2 8382 3529 Email: nswtag@stvincents.com.au www.nswtag.org.au Drugs for the treatment

More information

Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations

Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations Nancy E. Lane, MD Director, Center for Musculoskeletal Health Endowed Professor of Medicine and Rheumatology University

More information

2017 KDIGO Guidelines Update

2017 KDIGO Guidelines Update 2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation

More information

An Update on Osteoporosis Treatments

An Update on Osteoporosis Treatments An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and

More information

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012 Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco

More information

Guidelines and new evidence on CKD - MBD treatment

Guidelines and new evidence on CKD - MBD treatment Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,

More information

Metabolic Bone Disease (Past, Present and Future Challenges in the Management)

Metabolic Bone Disease (Past, Present and Future Challenges in the Management) Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading

More information

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but

More information

Magnesium Homeostasis

Magnesium Homeostasis ECTS PhD Training Course, Rome 3 rd September 2008 Disorders of Calcium, Phosphate h and Magnesium Homeostasis Richard Eastell Professor of Bone Metabolism Academic Unit of Bone Metabolism University of

More information

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),

More information

Hypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance

Hypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance Normal value Hypocalcemia Serum calcium Total mg/dl Ionized mg/dl Cord blood 9.0 ~ 11.5 5.0 ~ 6.o New born (1 st 24 hrs) 9.0 ~ 10.6 4.3 ~ 5.1 24~ 48 hrs 7.0 ~12.0 4.0 ~4.7 Child 8.8 ~10.8 4.8 ~4.92 There

More information

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco OSTEOMALACIA UPDATE Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco Nothing to Disclose 1 Case History 59 YO WM referred for evaluation of diffuse

More information

Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis

Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Tutorial for Specialist Portfolio Biomedical Scientists 03/02/2014 Dr Petros Kampanis Clinical Scientist 1. Calcium Most abundant

More information

Sensipar (cinacalcet)

Sensipar (cinacalcet) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:

More information

Pediatric CKD-MBD: pathophysiology and management

Pediatric CKD-MBD: pathophysiology and management Pediatric CKD-MBD: pathophysiology and management Justine Bacchetta, MD, PhD Reference Center for Rare Renal Diseases Reference Center for Rare Diseases of Calcium and Phosphate Bron, France Overview of

More information

Arizona Chapter AACE Paul D. Miller, M.D.

Arizona Chapter AACE Paul D. Miller, M.D. Arizona Chapter AACE Paul D. Miller, M.D. Management of fractures in CKD and atypical subtrochanteric femur fractures September 2018 Paul D. Miller, M.D. Disclosures: Amgen (Consultant, Advisory Board,

More information

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2 5 and on dialysis

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2 5 and on dialysis Nephrol Dial Transplant (2017) 1 14 doi: 10.1093/ndt/gfx080 Special Report Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages

More information

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,

More information

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral

More information

New biological targets for CKD- MBD: From the KDOQI to the

New biological targets for CKD- MBD: From the KDOQI to the New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr

More information

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2 5 and on dialysis

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2 5 and on dialysis Nephrol Dial Transplant (2017) 32: 1114 1127 doi: 10.1093/ndt/gfx080 Advance Access publication 1 June 2017 Clinical practice recommendations for treatment with active vitamin D analogues in children with

More information

Greater Manchester Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)

Greater Manchester Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) Greater Manchester Guidelines on the Management of (CKD-MBD) Classification: Clinical Guideline Lead Author: Smeeta Sinha, Consultant Nephrologist Additional author(s): Elizabeth Lamerton, Renal Pharmacist

More information

AACE ANNUAL MEETING. Osteoporois and Fractures across the 5 stages of Chronic Kidney Disease. Boston, Mass Paul D. Miller, M.

AACE ANNUAL MEETING. Osteoporois and Fractures across the 5 stages of Chronic Kidney Disease. Boston, Mass Paul D. Miller, M. AACE ANNUAL MEETING Osteoporois and Fractures across the 5 stages of Chronic Kidney Disease Boston, Mass 2018 Paul D. Miller, M.D Medical Director Paul D. Miller, M.D. Disclosures: Amgen (Consultant, Advisory

More information

Downloaded on T03:55:25Z

Downloaded on T03:55:25Z Title Author(s) Vascular calcification and mineral bone disorder in chronic kidney disease Kinsella, Sinéad Publication date 2013 Original citation Type of publication Rights Kinsella, S. 2013. Vascular

More information

Posttransplant Bone Disease. Budapest 2007

Posttransplant Bone Disease. Budapest 2007 Posttransplant Bone Disease Budapest 2007 Post-transplant bone disease 7 10 % of kidney transplanted patients develope a fracture. The risk is higher in postmenopausal female transplanted patients. Diabetic,

More information

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How

More information

Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano

Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (

More information

Sensipar. Sensipar (cinacalcet) Description

Sensipar. Sensipar (cinacalcet) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)

More information

Therapeutic golas in the treatment of CKD-MBD

Therapeutic golas in the treatment of CKD-MBD Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral

More information

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among

More information

Month/Year of Review: September 2012 Date of Last Review: September 2010

Month/Year of Review: September 2012 Date of Last Review: September 2010 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Southern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism

Southern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or

More information

Chronic Kidney Disease in Primary Care

Chronic Kidney Disease in Primary Care Clinical Stream Chronic Kidney Disease in Primary Care Dr Gerald Waters Dr Gerald Waters Renal Physician Chronic Kidney Disease Chronic Kidney Disease Normal functions of Kidneys Management of CKD Drugs

More information

Chronic kidney disease and the skeleton: Pathogenesis, complications and principles of management

Chronic kidney disease and the skeleton: Pathogenesis, complications and principles of management SA Orthopaedic Journal Autumn 2014 Vol 13 No 1 Page 29 Chronic kidney disease and the skeleton: Pathogenesis, complications and principles of management B Thibedi* BCur, MBChB EJ Raubenheimer** MChD, PhD,

More information

Malnutrition and Role of Nutrition in BMD:CKD

Malnutrition and Role of Nutrition in BMD:CKD Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition

More information

Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management

Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Complete this course and earn 1 CME POINT Dr. HO Chung Ping MBBS (HK), MRCP, FRCP (Glas, Edin), FHKCP,

More information

Approach to a patient with hypercalcemia

Approach to a patient with hypercalcemia Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical

More information

Secondary hyperparathyroidism in dialysis patients

Secondary hyperparathyroidism in dialysis patients Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++

More information

CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism

CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:

More information

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for

More information

Chronic Kidney Disease - Mineral Bone Disease (CKD-MBD) in Adults Information at Expert Level. Dr. BC Storey MB ChB MRCP DTM&H

Chronic Kidney Disease - Mineral Bone Disease (CKD-MBD) in Adults Information at Expert Level. Dr. BC Storey MB ChB MRCP DTM&H Expert Level European Dialysis and Transplant Nurses Association/ European Renal Care Association Chronic Kidney Disease - Mineral Bone Disease (CKD-MBD) in Adults Information at Expert Level. Dr. BC Storey

More information

CKD Mineral and Bone Disorder Management in Kidney Transplant Recipients

CKD Mineral and Bone Disorder Management in Kidney Transplant Recipients In Practice CKD Mineral and Bone Disorder Management in Kidney Transplant Recipients Hala M. Alshayeb, MD, 1 Michelle A. Josephson, MD, 1 and Stuart M. Sprague, DO 2 Kidney transplantation, the most effective

More information

AACE Southern States Chapter Lecture. Basics

AACE Southern States Chapter Lecture. Basics AACE Southern States Chapter Lecture Unusual Bone Cases Basics Osteoporosis Osteomalacia Renal Osteodystrophy Multiple Myeloma 1 Osteoporosis Definition Modeling, Bone Remodeling Bone Resorption > Bone

More information

PARATHYROID, VITAMIN D AND BONE

PARATHYROID, VITAMIN D AND BONE PARATHYROID, VITAMIN D AND BONE G M Kellerman Pathology North Hunter Service 30/01/2015 BIOLOGY OF BONE Bone consists of protein, polysaccharide components and mineral matrix. The mineral is hydroxylapatite,

More information

BONE AND MINERAL METABOLISM in the PD PATIENT

BONE AND MINERAL METABOLISM in the PD PATIENT BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,

More information

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD

More information

Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency. Spyridon Karras MD, Phd Endocrinologist

Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency. Spyridon Karras MD, Phd Endocrinologist Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency Spyridon Karras MD, Phd Endocrinologist Pregnancy We recommend a minimum intake of 600 international units of

More information

KDOQI COMMENTARY VOL 55, NO 5, MAY 2010

KDOQI COMMENTARY VOL 55, NO 5, MAY 2010 VOL 55, NO 5, MAY 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD Mineral and Bone Disorder (CKD-MBD) Katrin

More information

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement

More information

Treatment Options for Chronic Kidney

Treatment Options for Chronic Kidney Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition

More information

Drugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics

Drugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics Drugs Affecting Bone Rosa McCarty PhD Department of Pharmacology & Therapeutics rmccarty@unimelb.edu.au Objectives At the end of this lecture you should have gained: An understanding of bone metabolism

More information

NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT

NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral

More information

Kobe University Repository : Kernel

Kobe University Repository : Kernel Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms

More information

Bone impairment in pediatric CKD

Bone impairment in pediatric CKD A 16-year old girl arriving in the emergency room for seizures No significant medical past except orthopaedic surgery for bilateral genu valgum without any obvious etiology at the age of 14 years Bone

More information

Agents that Affect Bone & Mineral Homeostasis

Agents that Affect Bone & Mineral Homeostasis Agents that Affect Bone & Mineral Homeostasis 1 Agents that Affect Bone & Mineral Homeostasis Calcium and phosphate are the major mineral constituents of bone. They are also two of the most important minerals

More information

ELECTROLYTES RENAL SHO TEACHING

ELECTROLYTES RENAL SHO TEACHING ELECTROLYTES RENAL SHO TEACHING Metabolic Alkalosis 2 factors are responsible for generation and maintenance of metabolic alkalosis this includes a process that raises serum bicarbonate and a process that

More information

The Skeletal Response to Aging: There s No Bones About It!

The Skeletal Response to Aging: There s No Bones About It! The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium

More information

GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM

GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM 1.1 Serum levels of calcium, phosphorus, alkaline phosphatase, total CO 2, and PTH measured by a first-generation immunometric parathyroid hormone

More information

Clinician s Guide to Prevention and Treatment of Osteoporosis

Clinician s Guide to Prevention and Treatment of Osteoporosis Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening

More information

Bone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality.

Bone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality. Bone strength is proportional to bone mass, measured with DXA Bone quality depend on bone architecture, rate of bone turnover, quality of bone matrix. Bone turnover markers indicate the status of bone

More information

Management of CKD. Goce Spasovski, R. Macedonia

Management of CKD. Goce Spasovski, R. Macedonia Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD

More information

Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)

Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD) Oxford Kidney Unit Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD) Information for patients This leaflet will provide you with information about chronic kidney disease mineral bone disorder (CKD-MBD)

More information

Nottingham Renal and Transplant Unit

Nottingham Renal and Transplant Unit Nottingham Renal and Transplant Unit Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out

More information

Case study Group 2 presentation

Case study Group 2 presentation Case study Group 2 presentation Patient profile HN 3095-57 Female 60 years old Hometown : Sa Kaeo province Occupation : farmer No drug and food allergy Chief complain Left neck mass 10 years PTA that gradually

More information

Normal Bone Health and Bone Disease. Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017

Normal Bone Health and Bone Disease. Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017 Normal Bone Health and Bone Disease Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017 Learning outcomes Understand the structure and function of bone and articular cartilage Explain

More information

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis

More information

Clinical Guideline Bone chemistry management in adult renal patients on dialysis

Clinical Guideline Bone chemistry management in adult renal patients on dialysis Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L

More information

Bone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017

Bone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017 Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free

More information

Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012.

Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012. Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012 Disclosures I have no financial relationships with commercial interests,

More information

Chronic Kidney Disease Mineral Bone Disease

Chronic Kidney Disease Mineral Bone Disease NHS Logo here Chronic Kidney Disease Mineral Bone Disease (CKD-MBD) Patient Information Health & care information you can trust The Information Standard Certified Member Working together for better patient

More information

Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials

Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C. Craig, MBChB, PhD, Grahame J.

More information

CHRONIC KIDNEY DISEASE (CKD)

CHRONIC KIDNEY DISEASE (CKD) CHRONIC KIDNEY DISEASE (CKD) CKD implies longstanding (more than 3 months), and usually progressive, impairment in renal function. In many instances, no effective means are available to reverse the primary

More information

Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC

Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC Learning Goals Review guidelines for osteoporosis Consider

More information

Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)

Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism

More information

THE FIELD OF mineral metabolism and

THE FIELD OF mineral metabolism and SPECIAL REPORT Controversies in Bone and Mineral Metabolism in Chronic Kidney Disease A Bridge to Improving Healthcare Outcomes and Quality of Life Sharon M. Moe, MD, FACP, and Tilman B. Drüeke, MD, FRCP

More information

Cortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly

Cortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly Osteoporosis POOLE, K.E.S. & COMPSTON, J.E. (2006): Osteoporosis and its management. BMJ 333:1251-6. Physiology Cortical bone After age 40, gradually decreases 0.3-0.5% yearly, in both men and women Postmenopausally,

More information

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea

More information

Review Article Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management

Review Article Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management Advances in Nephrology, Article ID 727135, 7 pages http://dx.doi.org/10.1155/2014/727135 Review Article Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management Mahesan Anpalahan,

More information

THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE PATIENTS ON DIALYSIS:

THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE PATIENTS ON DIALYSIS: THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE PATIENTS ON DIALYSIS: A SYSTEMATIC REVIEW AND ECONOMIC EVALUATION Report commissioned

More information

Calcium, phosphate & magnesium regulation

Calcium, phosphate & magnesium regulation Calcium, phosphate & magnesium regulation Tim Arnett Department of Cell and Developmental Biology University College London Bone composition Treated with hydrochloric acid to dissolve mineral leaves organic

More information

Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD

Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD Biomarker der kardio-renalen Achse Mannheim, 20. Januar 2017 Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD Prof. Dr. med. Thomas Bernd Dschietzig Immundiagnostik AG, Bensheim Med. Klinik m.

More information